EDX Medical: Innovating Personalised Medicine and Cancer Care

EDX Medical Group PLC, based in Cambridge, England, has announced a new step forward in the fight against testicular cancer by signing an exclusive agreement with mirdetect GmbH. This partnership allows EDX to distribute the innovative

EDX Medical announced a new partnership, securing exclusive rights to distribute mirdetect GmbH’s M371 diagnostic test for testicular cancer. This Cambridge-based company is known for its innovative digital diagnostic tools, which target critical health issues, including

Cancer remains a significant global health issue and is the second leading cause of death in the U.S., following heart disease. While many cancers are linked to lifestyle, environmental, or unknown factors, some are hereditary, resulting

Genes are sections of DNA that carry instructions for building proteins, essential for the body’s proper functioning. Changes in these genes are known as single-gene variants. Genetic testing can reveal different types of gene variants, including

The Guardant Reveal liquid biopsy test has shown potential in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC), based on data from the COSMOS study, which has been published in Clinical

While cancer itself is not directly inherited, the genes passed down from your parents can influence your likelihood of developing certain cancers. In some families, cancer appears to be more common due to shared risk factors,

The last week of September marks an important moment dedicated to raising awareness about hereditary cancers. This time offers an opportunity to educate people about the genetic factors that can lead to certain types of cancer,

Genetic testing has become increasingly accessible in recent years. The process is straightforward: submit a sample of blood or saliva, and you can learn about your risk for cancer and other hereditary diseases. But is this

Recent years have seen liquid biopsy making significant strides in the healthcare landscape, especially for cancer detection. Known also as multi-cancer detection (MCD) or MCD assays, this test screens for various cancers using just a blood

The Guardant Reveal liquid biopsy test has demonstrated effectiveness in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC). This was shown through findings from the prospective COSMOS study, which were published

Cancer risk is shaped by a complex interplay of genetics, environment, medical history, and lifestyle. Within the realm of cancer genetics, inherited risk factors are a critical area of study. Understanding the influence of genetic variants,

Cambridge-based life science company, EDX Medical Group plc, has entered into a significant partnership with Caris Life Sciences, a US leader in next-generation AI TechBio and precision medicine. This agreement marks a major milestone for EDX

EDX Medical has entered into a distribution agreement with Caris Life Sciences, a US company specialising in AI-driven precision medicine. This collaboration will see both companies working together to distribute Caris’ advanced molecular profiling services across

EDX Medical Group, a UK-based medical diagnostics company, has entered into a distribution agreement with Caris Life Sciences, a US-based AI and precision medicine firm. This partnership will see the two companies work together to distribute